Share Options (Tables)

9 Months Ended

Sep. 30, 2015

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Option Plans

A summary of the status of the Company’s option plans as of September 30, 2015 (unaudited) and changes during the period then ended is presented below:

	Period ended September 30, 2015 (unaudited)
	Number of options			Weighted average exercise price		Aggregate intrinsic value
Outstanding at beginning of period		7,426,159		$	3.98
Granted		2,718,127			17.02
Exercised		(2,512	)		7.36
Forfeited and cancelled		(191,276	)		8.39
Outstanding at end of period		9,950,498		$	7.46	$	144,651
Exercisable options		5,163,286		$	2.86	$	98,819
Vested and expected to vest		8,968,053		$	5.96	$	143,856

Stock Option Outstanding Separated into Ranges of Exercise Prices

The options outstanding as of September 30, 2015 (unaudited) have been separated into ranges of exercise prices, as follows:

Exercise price	Number of options outstanding as of September 30, 2015		Weighted average remaining contractual term		Number of options exercisable as of September 30, 2015		Weighted average remaining contractual term
			(years)				(years)
0.01		98,995		0.46		98,995		0.46
0.17		1,403,857		0.96		1,403,857		0.96
0.23		440,531		3.68		440,531		3.68
0.38		488,331		5.04		488,331		5.04
3.44		1,779,072		6.13		1,350,491		6.12
6.72		940,424		6.93		687,525		6.93
6.83		92,227		7.20		46,390		7.20
7.03		613,174		7.39		306,570		7.39
7.04		137,321		7.72		69,311		7.72
7.28		167,921		7.90		79,366		7.90
7.48		504,365		8.39		127,555		8.39
7.52		116,769		8.49		29,186		8.49
7.58		52,032		8.74		13,006		8.74
7.73		431,053		9.02		22,172		8.87
14.37		1,616,012		9.41		-		-
15.60		146,926		9.57		-		-
22.00 (1)		921,488		10.00		-		-
		9,950,498		6.62		5,163,286		4.63

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non – cash share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine months ended September 30, 2015 and 2014 (unaudited) was comprised as follows:

	Three months ended September 30,				Nine months ended September 30,
	2015		2014		2015		2014
	Unaudited				Unaudited
Cost of revenues	$	35	$	14	$	54	$	31
Research, development and clinical trials		668		254		1,717		543
Sales and marketing		571		262		1,550		807
General and administrative		1,654		675		4,051		1,973
Total share-based compensation expense	$	2,928	$	1,205	$	7,372	$	3,354